Head-to-head evidence
Inclisiran vs Tafolecimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Inclisiran · Leqvio
Marketed by Novartis and partners
NCT03397121 · Phase 3 · completed
The trial randomly assigned 482 participants to double-blind inclisiran or placebo, with 242 receiving inclisiran and 240 receiving placebo. Both primary LDL-C comparisons were statistically significant in favor of inclisiran, but LDL-C is a surrogate laboratory endpoint rather than a hard clinical outcome, supporting a moderate evidence grade.
Next expected readout: October 2026 · NCT05360446 (registry estimate)
Tafolecimab · Sintbilo
Marketed by Innovent Biologics
NCT04289285 · Phase 3 · completed
This randomized, quadruple-blind, placebo-controlled trial enrolled 804 participants and met its primary endpoint: LDL cholesterol fell by roughly 57 to 65 percentage points more than placebo across both dosing regimens, a highly statistically significant result.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Inclisiran's landscape · Tafolecimab's landscape